Hayley M. Rogers
FSA, MAAA
Consulting Actuary
Seattle, WA, US
Hayley Rogers is a consulting actuary with the Seattle office of Milliman. She joined the firm in 2008.
Experience
Hayley is responsible for managing a wide variety of clients, projects, and products. Her clients include insurance companies, managed care organizations, state government agencies, and stop loss carriers. Types of clients supported include:
- Medicare Advantage plans
- State Medicaid agencies
- Commercial health insurers
- Stop loss pricing
- The Department of Veterans Affairs
Her consulting assignments have included:
- Evaluating and certifying liabilities and assets for several insurers as part of annual statutory financial submissions.
- Preparing Medicare Advantage bids for multiple organizations, including both standard actuarial functions and strategic support. This work has been completed on behalf of Institutional Special Need Plans (I-SNPs) and general enrollment plans.
- Developing COVID-19 projection models, leading Milliman’s COVID-19 impact research, and assisting clients project the medical impact through 2022.
- Calculating capitation rates for multiple state Medicaid agencies.
Publications and Presentations
- Article: Estimating the impact of COVID-19 on healthcare costs in 2020: Key factors of the cost trajectory 23 April 2020 - By Hayley Rogers, Charlie Mills, Matthew Kramer.
- Webinar: Estimating the impact of COVID-19 on healthcare costs in 2020.
- Video: People everywhere: How 2020 has us living our mission like never before. From theory to the front lines: one healthcare consultant's harrowing COVID-19 story.
Professional Designations
- Member, American Academy of Actuaries, 2013
- Fellow, Society of Actuaries (FSA), 2016
- Milliman Global Health Practice Director Outstanding Service Award, 2020
Education
- BA, Applied Mathematics and Economics – Whitman College, 2008
Publications
Read their latest work
Article
Star Ratings in Retrograde: Decoding the 2025 Decline
06 November 2024 - by Hayley M. Rogers, Matthew Smith
We discuss the causes and revenue implications in the historic decline in Star Ratings for Medicare Advantage and accompanying prescription drug contracts.
Article
Recalculating Medicare Advantage: Potential SCAN and Elevance ruling implications for MA stakeholders
12 June 2024 - by Hayley M. Rogers, Matthew Smith
A recent order for CMS to recalculate Star Ratings could eventually result in a 0.5-point increase for more than 60 Part C contracts under Medicare Advantage plans.
Article
Leveraging operational excellence: Enhancing Medicare Star Ratings through effective adaptation
06 March 2024 - by Rachel Ferguson, Bryce Platt, Hayley M. Rogers
Given the impending changes to the Medicare Advantage Star Ratings, organizations should proactively act to preserve or improve their current ratings.
Article
The next stage of Star Ratings evolution: 2025 Proposed Rule and beyond
27 November 2023 - by Hayley M. Rogers, Matthew Smith, Mike Yurkovic
Healthcare stakeholders must thoroughly evaluate CMS’s 2025 Proposed Rule, including its impacts and integration into the operations of Medicare Advantage plans.
Article
Observations on the employer stop-loss market: 2023 survey
02 November 2023 - by Robert Bachler, Hayley M. Rogers, Jakob Finney
We detail our survey of 31 employer stop-loss carriers, including their portfolio characteristics and underwriting results.
Article
The future is now: 2024 Star Ratings release
30 October 2023 - by Hayley M. Rogers, Matthew Smith, Philip Nelson, Mike Yurkovic
As health plans integrate the latest Medicare Advantage Star Ratings, they should proactively consider how to adjust processes to be best prepared.
Article
Future of Medicare Star Ratings: The reimagined CMS bonus system
06 October 2023 - by Hayley M. Rogers, Matthew Smith, Mike Yurkovic
With significant changes coming to the Medicare Star Ratings, Medicare Advantage organizations (MAOs) need to adapt to maintain or recover their current tiers.
Article
Estimating the impact of COVID-19 on healthcare costs in 2020: Key factors of the cost trajectory
23 April 2020 - by Hayley M. Rogers, Charlie Mills, Emma Kramer
The deferral and elimination of care during the COVID-19 pandemic could mean a net reduction in medical costs for healthcare payers by at least $75 billion and as much as $575 billion if the deferral and elimination of care continues through the end of 2020.